Drug intelligence / Profile preview

2-hydroxy-3,5-diiodobenzoic acid

Development stage: Unknown
Modality: Small Molecules

Overview

2-Hydroxy-3,5-diiodobenzoic acid is a derivative of salicylic acid with two iodine atoms at the 3 and 5 positions. It is classified as a small molecule and has been studied for its potential biological activities such as antimicrobial and antifungal effects. The compound has also been investigated for possible roles in treating conditions related to iodine deficiency and hormonal imbalances. Its mechanism of action includes inhibition of the endothelin-1 receptor[1][4]. The compound is not approved for any medical use in the US or elsewhere[1].

Other names: 3,5-diiodosalicylic acid2-hydroxy-3,5-diiodobenzenecarboxylic acid3,5-diiodo-2-hydroxybenzoic acid

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on 2-hydroxy-3,5-diiodobenzoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-hydroxy-3,5-diiodobenzoic acid.

Explore the full profile